TG Therapeutics (TGTX) Could Be 24% Undervalued As BRIUMVI Expansion Stays In Focus

TG Therapeutics (TGTX) has drawn fresh attention after recent trading left the share price at $52.95, with the move coming alongside mixed short term returns but notable gains over the past year.

For context, TG Therapeutics has a 1-day share price gain of 1.46% but is down 5.07% over the past week and 10.35% over the past 90 days. The year-to-date share price return of 80.84% and 3-year total shareholder return above 6x indicate that longer term momentum has been strong even as shorter term sentiment has cooled.

See how TG Therapeutics compares with other high momentum healthcare names by reviewing the hand picked 34 healthcare AI stocks that have attracted investors' attention this year.

TG Therapeutics looks like a powerful growth story on recent numbers, yet the stock now trades around $52.95 after a sharp multi year run. Is that price still grounded in what investors actually get for the business today?

Most Popular Narrative: 24% Undervalued

On the most followed narrative, TG Therapeutics is framed as worth $69.71 per share, compared with the recent close at $52.95, which puts the focus squarely on whether BRIUMVI can support that gap through execution across multiple autoimmune indications.

The planned launch of subcutaneous BRIUMVI remains a key upcoming catalyst, as it targets the 35 to 40% of the anti CD20 multiple sclerosis market that is currently in self administered products where TG Therapeutics does not yet participate. This could materially affect future revenue and earnings. The fully enrolled Phase 3 program for subcutaneous BRIUMVI, supported by Phase 1 data indicating around 60% bioavailability and acceptable injection tolerability and guided toward a potential 2028 launch, could allow TG Therapeutics to participate in both infusion and self administered anti CD20 segments and affect top line growth and operating leverage.

See why 69 investors see TG Therapeutics as 24% undervalued.

Result: Fair Value of $69.71 (UNDERVALUED)

Still, the bullish TG Therapeutics story can crack if BRIUMVI spending keeps squeezing profits or if governance investigations deepen and distract management at key execution moments.

Find out about the key risks to this TG Therapeutics narrative.

Next Steps

Sentiment on TG Therapeutics is clearly split, with strong enthusiasm sitting right beside pointed concerns. Consider moving quickly and weighing the evidence for yourself by reviewing the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond TG Therapeutics?

If TG Therapeutics has sharpened your focus, do not stop here. Broaden your watchlist now with targeted stock ideas that match your goals before others get there first.

• Target potential mispricing by scanning a curated set of companies screened as 29 high quality undervalued stocks that may warrant a closer look on your dashboard.
• Strengthen your income stream by reviewing stocks highlighted as 8 dividend fortresses and see which payouts line up with your return expectations.
• Dial down risk while staying invested by filtering for a 31 resilient stocks with low risk scores that could help stabilise your portfolio when markets turn choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com